<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256542</url>
  </required_header>
  <id_info>
    <org_study_id>URG-101</org_study_id>
    <nct_id>NCT00256542</nct_id>
  </id_info>
  <brief_title>Study of U101 for Bladder Pain and/or Urgency</brief_title>
  <official_title>A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urigen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urigen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravesical U101 (alkalinized
      lidocaine-heparin) treatment reduces the symptoms of pelvic pain and/or urgency of bladder
      origin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date>September 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall improvement in combined symptoms of pain and urgency at 3 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in pain on ten point scale at 3 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in urgency on ten point scale at 3 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of voids/24 hours</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average void volume</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in PUF score (pelvic pain, urgency/frequency) at 3 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in O'Leary-Sant score at 3 weeks</measure>
  </secondary_outcome>
  <enrollment>90</enrollment>
  <condition>Pelvic Pain</condition>
  <condition>Interstitial Cystitis</condition>
  <condition>Bladder Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alkalinized Lidocaine-Heparin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects at least 18 years of age.

          -  Subjects must have given written informed consent to participate in this trial.

          -  All female subjects, except those who are post-menopausal and/or surgically
             sterilized, must consent to use two medically acceptable methods of contraception
             throughout the entire study period. Medically acceptable methods of contraception that
             may be used by the subject and/or her partner include: abstinence, birth control
             pills, diaphragm with spermicide, intrauterine device (IUD), condom and foam, vaginal
             spermicidal suppository, progestin implant, and Depo-Provera injections.

          -  Subjects must have had symptoms of pelvic pain and/or urgency.

          -  Medical history and physical examination results must be clinically acceptable to the
             Investigator. Medical Monitor may evaluate subjects who donâ€™t meet eligibility
             criteria.

          -  Female subjects currently using hormone therapy (HT) must have been using HT for at
             least 3 months.

        Exclusion Criteria:

          -  Subjects less than 18 years of age.

          -  Subjects with known hypersensitivity to heparin or lidocaine.

          -  Female subjects who have a positive pregnancy test at the time of screening, who are
             pregnant or lactating, or who are planning to become pregnant during the study period.

          -  Subjects who are chronic users of narcotics or who are using any narcotics at the time
             of study entry.

          -  Subjects who have hepatic disease or clinically significant abnormal liver function
             tests (more than twice the upper limit of the normal range).

          -  Subjects who do not expect to be available for the entire duration of the study.

          -  Subjects with any coexisting significant medical condition that is likely to interfere
             with study procedures (cardiovascular, hematological, central nervous system,
             pulmonary, renal, etc.)

          -  Subjects who have been treated with dimethyl sulfoxide (DMSO) or other bladder
             instillation therapies within three months prior to study entry.

          -  Subjects who have had cystoscopic dilatation of their bladder or urethra within three
             months of study entry.

          -  Subjects who have taken or used any investigational drug or device within 30 days
             before the start of the study, or who are currently enrolled in another
             investigational study.

          -  Subjects contemplating having or scheduled for any invasive surgical procedures during
             the study period.

          -  Subjects who are unwilling or unable to abide by the requirements of the study.

          -  History of gastrointestinal (GI) bleeding

          -  Active bleeding from any source

          -  Screening activated partial thromboplastin time (aPTT) above normal limits

          -  Systolic blood pressure (BP) &gt; 180 mmHg or &lt; 90 mmHg at Screening.

          -  Subjects with an actively bleeding lesion/area in the bladder as detected by
             urinalysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Lowell Parsons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Urology</name>
      <address>
        <city>Cartersville</city>
        <state>Georgia</state>
        <zip>30120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Good Samaritan</name>
      <address>
        <city>Centralia</city>
        <state>Illinois</state>
        <zip>62801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urogynecology Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Michigan Health Centers</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Park Urology</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Specialists of Oklahoma, Inc.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whitmore Urology Office</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology. 2005 Jan;65(1):45-8.</citation>
    <PMID>15667861</PMID>
  </reference>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2005</study_first_submitted>
  <study_first_submitted_qc>November 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>September 28, 2006</last_update_submitted>
  <last_update_submitted_qc>September 28, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2006</last_update_posted>
  <keyword>interstitial cystitis</keyword>
  <keyword>pelvic pain</keyword>
  <keyword>urgency</keyword>
  <keyword>frequency</keyword>
  <keyword>Pelvic Pain and/or Urgency of Bladder Origin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Pain</mesh_term>
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
    <mesh_term>Urinary Bladder Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

